Breaking News

Valeant To Acquire Aesthetic Device Maker

December 16, 2013

Solta Medical is company behind Fraxel, Thermage and others.

Valeant Pharmaceuticals has entered into a definitive agreement to acquire all of the outstanding common stock of skin aesthetics device maker Solta Medical, Inc for approximately $250 million. The deal is expected to close in the first quarter of 2014.

Solta designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications.  Solta's products include the Thermage CPT system that provides non-invasive treatment options using radiofrequency energy for skin tightening, the Fraxel repair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, the Clear + Brilliant system to improve skin texture and help prevent the signs of aging skin, and the Liposonix system that destroys unwanted fat cells resulting in waist circumference reduction.  Solta's total revenue were approximately $145 million last year.

"The acquisition of Solta will bring tremendous value to Valeant's current aesthetic portfolio and together with our previous acquisitions, will create the broadest aesthetic portfolio in the industry," stated J. Michael Pearson, chairman and CEO of Valeant.  "Solta's leading aesthetic devices are a natural fit with Valeant's facial injectables, professional skin care products and physician dispensed products and will establish Valeant in a strong leadership position as we continue to build our presence in the aesthetic market.  Moreover, this transaction will further enhance our ability to offer dermatologists and plastic surgeons the most comprehensive aesthetic product offering."

According to Mark Sieczkarek, chairman of the board and interim CEO of Solta Medical, Valeant “has a proven track record of successfully integrating a number of major acquisitions into their portfolio and has established a significant presence in the aesthetics market.  The addition of Solta's industry leading brands and global sales organization creates a very compelling platform for future growth in the medical aesthetic segment.  Our entire team looks forward to executing a smooth transition of our operations into the Valeant organization."

Related End-User Markets:

blog comments powered by Disqus
  • Witch

    Witch's Brew: Dickinson's celebrates milestone in 2016

    Christine Esposito, Associate Editor||February 1, 2016
    Dickinson’s celebrates 150 years of witch hazel skin care with the biggest line expansion in the company’s history.

  • From Research to Retail

    Tom Branna, Editorial Director||February 1, 2016
    What began as research on skin disorders led a dermatologist and his father to create their own skin care formulas.

  • 5 Things I Learned

    5 Things I Learned

    January 15, 2016
    The Avon & Women’s Dermatologic Society Mentorship Program. Dr. Sabrina Fabi (left) and Dr. Kimberly Jerdan.

  • Burgeoning Beauty

    Burgeoning Beauty

    Melissa Meisel, Associate Editor||January 4, 2016
    A look at trailblazers for 2016 and beyond.

  • Testing for Sustainable Preservatives

    Adam P. Byrne, William Michael Hart-Cooper, Kaj Johnson, Larry H. Stanker, Dominic W. S. Wong, William J. Orts||January 4, 2016
    A rapid, inexpensive and qualitative protocol for determining microbial growth inhibition.

  • In-Cosmetics Paris Has Sights on US

    In-Cosmetics Paris Has Sights on US

    Imogen Matthews , In-Cosmetics||December 2, 2015
    Market focus is on the USA.